|
Pasritamig Clinical Trials
4 actively recruiting trials across 3 locations
No change since May 2026
Also known as: JNJ-78278343
Pipeline
Phase 1: 2Phase 3: 2
Top Sponsors
- Janssen Research & Development, LLC4
Indications
- Cancer4
- Metastatic Castration-resistant Prostate Neoplasms2
- Metastatic Hormone-sensitive Prostate Cancer1
- Prostatic Neoplasms, Castration-Resistant1
- Prostatic Neoplasms1
Sarasota, Florida2 trials
A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer
Florida Cancer Specialists
Phase 1
A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
Florida Cancer Specialists
Phase 1
Chandler, Arizona1 trial
La Jolla, California1 trial
A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
University of California at San Diego
Phase 3
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.